Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
AssigneeGuangdong Raynovent Biotech Co., Ltd.
InventorsChaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
Life of this patent
Estimating the term…
Abstract
Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
Claims15
A crystal form of Compound 1 comprising a crystal form A, a crystal form B, a crystal form C, a crystal form D or a crystal form E,
- wherein,
- the crystal form A has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 4.47±0.2°, 7.80±0.2°, 12.61±0.2°, 13.25±0.2°, 16.32±0.2°;
- the crystal form B has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 13.55±0.2°, 15.94±0.2°, 17.36±0.2°, 22.41±0.2°, 24.16±0.2°, 24.78±0.2°;
- the crystal form C has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 13.29±0.2°, 15.58±0.2°, 16.21±0.2°, 19.84±0.2°, 24.95±0.2°;
- the crystal form D has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 6.70±0.2°, 11.30±0.2°, 11.76±0.2°, 15.52±0.2°, 16.35±0.2°;
- the crystal form E has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 4.51±0.2°, 6.68±0.2°, 11.79±0.2°, 13.62±0.2°.
A hydrochloride salt of Formula (I) comprising a crystal form F having an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 11.64±0.2°, 13.32±0.2°, 14.02±0.2°, 20.06±0.2°, 24.22±0.2°
A p-toluenesulfonate salt of Formula (II) comprising a crystal form G having an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 4.84±0.2°, 9.93±0.2°, 15.43±0.2°, 19.48±0.2°, 19.93±0.2°
An ethanesulfonate salt of Formula (III) comprising a crystal form H having an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 7.80±0.2°, 12.53±0.2°, 13.11±0.2°, 17.78±0.2°, 21.90±0.2°
A methanesulfonate salt of Formula (IV) comprising a crystal form J, a crystal form K, a crystal form L or a crystal form M, wherein,
- the crystal form J has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 7.88±0.2°, 12.58±0.2°, 15.02±0.2°, 21.28±0.2°, 22.00±0.2°, 27.35±0.2°;
- the crystal form K has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 8.02±0.2°, 16.52±0.2°, 18.10±0.2°, 20.35±0.2°, 22.10±0.2°, 23.27±0.2°;
- the crystal form L has an X-ray powder diffraction pattern with characteristic diffraction peaks at angle 2θ of:
- 18.06±0.2°, 21.35±0.2°, 22.05±0.2°, 24.94±0.2°;
- the crystal form M has an X-ray powder diffraction pattern with characteristic diffraction peaks at angles 2θ of:
- 9.68±0.2°, 20.78±0.2°, 23.15±0.2°, 29.82±0.2°.
Dependencies are inferred from the claim text.